NCT02056600已完成1 期
A Randomized, Open-label, Single Dose, Two-way Crossover Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of the Combination of Gemigliptin/Metformin HCl Sustained Release 50/1000mg in Comparison to Each Component Gemigliptin 50mg and Metformin HCl Extended Release 1000mg Administered in Healthy Male Volunteers
LG Life Sciences1 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2014年3月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- AUClast
研究概览
简要总结
This study is to evaluate the safety/tolerability and pharmacokinetics of the combinations of gemigliptin 50mg and metformin HCl extended release 1000mg in comparison to each component administered in healthy male volunteers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy male adults at age between 20 to 45 at the time of the screening
- •ThoseSubjects whose BMI measurement at screening visit is between 18 and 27 kg/m2
- •Subjects with fasting plasma glucose (FPG) of 70-125 mg/dL at screening visit
- •Subject who has voluntarily decided to participate in this clinical trial and onsented in writing
排除标准
- •Subjects who have a past or present clinically significant disease such as hepatic, renal, gastrointestinal, respiratory, musculoskeletal, endocrine, neurological, hemato-oncological, or cardiovascular disorder
- •Subjects who have a past history of gastrointestinal disease (e.g. Crohn's disease, ulcer, etc.) or surgery (however, simple appendectomy and hernioplasty are not included) that can affect the absorption of drugs
- •Subjects with a medical history of allergic reaction to other drugs including the investigational products or clinically significant hypersensitivity reaction
- •Subjects who have a history of drug abuse
- •Subjects who have shown positive reaction to drugs that may be abused from a urine drug screening
- •Subjects who took other investigational product in other trials within 90 days before the first administration of this investigational product
- •Subjects who had whole blood donation within 60 days or component blood donation within 30 days before the first administration of the investigational product, or transfusion within 30 days before the first administration
- •Subjects who have taken a drug which is expected to have an effect on the clinical trial within 14 days before the date of the first administration of the investigational product or have had any food that is expected to have an effect on the clinical trial within 7 days (e.g. drinks containing caffeine, grapefruit juice, etc.)
- •Subjects who have had alcohol containing drinks 3 times or more per week within one month before the screening visit or cannot abstain from drinking after completing the informed consent form for the participation in the study to the end of the clinical trial
- •Subjects who have smoker more than 10 cigarettes per day within the recent one month at the screening visit or cannot refrain from smoking the clinical trial period
- •In the vital signs measured in sitting position at the screening visit, subjects who have showed a systolic blood pressure of < 90 mmHg or > 145 mmHg, a diastolic blood pressure of > 95 mmHg or < 60 mmHg) , or a pulse rate of > 110 bpm or < 40 bpm
- •Subjects who showed the following findings in the tests conducted during the screening period:
- •In excess of 1.5 times the upper normal limit (UNL) in hepatic enzyme (AST and ALT) values
- •The creatinine clearance calculated by Cockcroft-Gault equation is 80 mL/min or less
- •Positive result in serum test (hepatitis type B test, hepatitis type C test, Human Immunodeficiency Virus (HIV) test, syphilis test)
- •QTc > 450 msec in ECG or a clinically significant abnormal rhythm
- •Subjects who are considered to be unsuitable in conducting the clinical trial for other reason at the principal investigator's discretionary judgment
研究组 & 干预措施
G+M
Experimental
Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg
干预措施: gemigliptin and metformin HCl extended release (Drug)
C
Experimental
Combination of gemigliptin50mg/metformin HCl sustained release 1000mg
干预措施: gemigliptin/metformin HCl sustained release (Drug)
结局指标
主要结局
AUClast
时间窗: up to 48h post-dose
To evaluate AUClast of gemigliptin and metformin
Cmax
时间窗: up to 48h post-dose
To evaluate Cmax of gemigliptin and metformin
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
BE Study of the Combinations of Gemigliptin 50mg and Rosuvastatin 20mg in Comparison to Each Component Administered AloneHealthyNCT02670070LG Life Sciences37
已完成
1 期
BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 500mg in Comparison to Each Component Administered AloneHealthyNCT01595880LG Life Sciences29
已完成
1 期
BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 1000mg in Comparison to Each Component Administered AloneHealthyNCT01662674LG Life Sciences27
已完成
1 期
A Clinical Trial to Compare the Safety and Pharmacokinetic Characteristics of Combination of Rosuvastatin and CS-866 and DWJ1276Healthy VolunteersNCT01493856Daewoong Pharmaceutical Co. LTD.58
已完成
4 期
Study to Evaluate the Safety of Co-administration of GSK Biologicals' Poliorix and Infanrix in Healthy Children in RussiaPoliomyelitisNCT01094171GlaxoSmithKline400